ONCODNA
OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives.
The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank with the significant support of SFPI-FPIM. Historical shareholders together with CPH Bank, Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and SRIW have also participated. This represents another landmark achievement after the €8 million Series A fundraising closed in September 2016.
OncoDNA is now maximizing the fast and proper rollout of its oncology clinical decision support software OncoKDM® with the objective of becoming the European leader in oncogenomic data interpretation and reporting to further support molecular laboratories, healthcare professionals and the pharma industry in their daily research and clinical practice.
Jean-Pol Detiffe, Founder & Chief Executive Officer at OncoDNA : “We are delighted to have successfully raised sufficient new capital from such quality investors who will enable us to grow and increase our support to oncologists and cancer patients with our data driven solutions. OncoDNA is already positioned as the European champion for cancer precision medicine as we built a worldwide network of more than several thousand oncologists. Our next move is to connect molecular laboratories to our advanced data interpretation tools, which we pride ourselves on now being possible thanks to the support of our new investors.”
Guy Geldhof, Partner at Vesalius Biocapital III S.C.A. SICAR said: “We are excited about co-leading the Series B investment in OncoDNA. It is thrilling to work with a team that has both world class experience in genomic molecular profiling and a strong desire to serve patients by offering best-in-class support to oncology professionals. We are confident OncoDNA will accelerate the development and commercialization of its valuable new solutions, especially through closer collaborations with the biopharma industry, with the final objective of contributing to better healthcare .”
Robert Schier, Partner at Swisscanto (CH) Private Equity Switzerland Growth I KmGK added: “OncoDNA has grown significantly over the past years and are continuing to add the necessary clinical expertise and know-how to act upon its mission. Its disruptive vision and highly integrated market approach make it to be the perfect candidate to rapidly become the European leader in oncology big data. We are delighted to partner with OncoDNA as we firmly believe the company contributes to both a more sustainable healthcare system and improved patient health outcomes.”
“Considering our important investment in OncoDNA, alongside players like Vesalius Biocapital III and Swisscanto, we are convinced that the company has all the necessary means at a key moment of its development to successfully carry out appropriate projects to assist and support oncologists in prescribing the most optimal therapeutic treatments to patients. We are happy to count on the support of our colleagues from SRIW and Sambrinvest as historical stakeholders” concluded François Fontaine, at SFPI-FPIM.
OncoDNA
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide with NGS facilities who would like to reach the same level of expertise, we provide them with state-of-the-art interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, employs 50 employees in 4 countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200214005149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev and International Cricket Council Announce Landmark Global Partnership11.12.2025 10:31:00 CET | Press release
World’s Leading Brewer becomes the Official Beer Partner of the ICC The International Cricket Council (ICC) announced AB InBev (Euronext: ABI) (NYSE: BUD) (MEXBOL: ANB) (JSE: ANH), the world’s leading brewer, will become the Official Beer Partner for all major ICC tournaments starting in 2026. The partnership will be led by Budweiser 0.0, Budweiser’s no-alcohol beer in India, with other ABI mega brands activating in Europe and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211250826/en/ AB InBev and ICC announce global partnership From attending a match live in-stadium to watching one at a bar or pub with friends, with a lower alcohol-by-volume (ABV) and no-alcohol options like Budweiser 0.0, beer is the natural choice to enjoy responsibly. Through this partnership with the ICC, AB InBev will create more moments of cheers, choice and celebration for cricket fans of legal drinking age all over the world. ICC CEO, S
Spark Reply and Concept Reply Promote CO₂-optimised Charging Together With BMW11.12.2025 10:30:00 CET | Press release
Spark Reply, specialists in design and user experience, and Concept Reply, IoT and AI technology experts within the Reply Group, have developed a smart app for the BMW group as part of a research project that actively encourages electric vehicle drivers to adopt low-carbon charging habits. The “COOL” feature within the BMW Prototyping App “360° Mobility” analyses the current electricity mix and shows users in real time when it is at its cleanest. Playful interactions and personalised AI-generated images further motivate drivers to make more sustainable choices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211155452/en/ In a post pilot survey, 73 per cent of participants stated that they were willing to make an extra effort to charge with reduced CO₂ emissions, such as by setting a charging window in their app. This proves that 'COOL' can measurably reduce the carbon footprint of everyday electric driving. Electric mobil
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 09:00:00 CET | Press release
Thales launches its new AI Security Fabric, delivering the first runtime security capabilities designed to protect Agentic AI, LLM-powered applications, enterprise data, and identities.New capabilities address emerging AI-specific threats—including prompt injection, data leakage, model manipulation, and insecure RAG pipelines—helping organizations innovate safely while maintaining compliance.With upcoming 2026 enhancements, Thales aims to provide a comprehensive security layer for AI ecosystems, enabling enterprises to confidently scale AI adoption across cloud and on-premises environments. AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in A
Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 09:00:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 08:30:00 CET | Press release
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader Structure Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom